Impact of Sacubitril–Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction

Pericàs, Pere; Mas-Lladó, Caterina; Ramis-Barceló, Maria F; Valadrón, Isabel; Mora, Marta Noris; Marquez, L.; Colino, Rosa González; Albertí, José Francisco Forteza; Disdier, Vicente Peral; Rosselló, Xavier

doi:10.1007/s40292-021-00437-x

Cited by 11 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sacubitril–valsartan is an angiotensin receptor–neprilysin inhibitor which applied to treat that heart failure. [10] Neprilysin degrades biologically active natriuretic peptides, including atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide, but not the biologically inert NT-proBNP, which is not a substrate for this enzyme. [11] In the PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial,[ 12 13 ] the use of sacubitril–valsartan resulted in a lower risk of death for heart failure than enalapril in this population.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials

Lin¹,

Zhou²,

Xie³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used Cochrane Library, PubMed web of science, CNKI, VIP, Medline, ISI Web of Science, CBMdisc, and Wanfang database to conduct a systematic literature research. A fixed-effects model was used to evaluate the standardized mean differences (SMDs) with 95% confidence intervals. We conducted sensitivity analysis and analyzed publication bias to comprehensively estimate the efficacy and safety of sacubitril-valsartan in patients with heart failure. Results: Among 132 retrieved studies, 5 relevant RCTs were included in the meta-analysis. The result showed that left ventricular ejection fraction (LVEF) was improved after sacubitril-valsartan in patients with heart failure, with an SMD (95% CI of 1.1 [1.01, 1.19] and P < .00001 fixed-effects model). Combined outcome indicators showed that, combined outcome indicators showed that, compared with control group, the left ventricular volume index (LAVI) (WMD = −2.18, 95% CI [−3.63, −0.74], P = .003), the E/e’ (WMD = −1.01, 95% CI [−1.89, −0.12], P = .03), the cardiovascular death (RR = 0.89, 95% CI [0.83, 0.96], P = .003], and the rehospitalization rate of heart failure (RR = 0.83, 95% CI [0.78, 0.88], P < .01) decreased more significantly, but it had no effect on renal function (WMD = 0.74, 95% CI [0.54, 1.01], P = .06). Conclusions: The present meta-analysis suggested that sacubitril-valsartan may improve the cardiac function of heart failure. Given the limited number of included studies, additional large sample-size RCTs are required to determine the long-term effect of cardiac function of sacubitril-valsartan in patients with heart failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials

Lin¹,

Zhou²,

Xie³

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…Diastolic indices also concurrently improve with ARNI, demonstrating reduction in LAVi by 4.4% (3.99 to 4.73 [CI 95%]) and E/e′ by a value of 1.23 (0.83–1.63 [CI 95%]), at 6 months 44 . These changes in LAVi and E/e′ with ARNI therapy has been demonstrated across multiple studies 44,45,53,54 . Pericas et al demonstrated improved E/A, E/e′ as well as improved LAV without change in LA EF 54 …”

Section: Cardiac Remodelling With Angiotensin Receptor Neprilysin Inh...mentioning

confidence: 96%

Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure

Kodsi,

Makarious,

Gan

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

Recently established heart failure therapies, including sodium glucose co‐transporter 2 inhibitors, angiotensin‐neprilysin inhibitors, and cardiac resynchronization therapy, have led to both clinical and structural improvements. Reverse remodelling describes the structural and functional responses to therapy and has been shown to correlate with patients' clinical response, acting as a biomarker for treatment success. The introduction of these new therapeutic agents in addition to advances in non‐invasive cardiac imaging has led to an expansion in the evaluation and the validation of cardiac reverse remodelling. Methods including volumetric changes as well as strain and myocardial work have all been shown to be non‐invasive end‐points of reverse remodelling, correlating with clinical outcomes. Our review summarizes the current available evidence on reverse remodelling in heart failure by the non‐invasive cardiac imaging techniques, in particular transthoracic echocardiography.

show abstract

“…The benefit of ARNI (compared to ACEi enalapril) in patients with HFrEF was demonstrated in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor–Neprilysin Inhibitor with Angiotensin-Converting–Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial [ 28 ] which showed significant (by 20%) reduction of the composite endpoint of cardiovascular death or heart failure hospitalization with ARNI. ARNI therapy seemed promising in patients with HFpEF, considering the data from phase 2 clinical trial [ 29 ] which showed in patients with HFpEF a greater reduction of heart failure biomarkers with ARNI than with valsartan alone, and promising data from studies on animal models [ 30 , 31 ] or data regarding beneficial effect of ARNI on left ventricular diastolic function coming from small postmarketing study [ 32 ]. However, these promises were not verified in PARAGON-HF (The Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) trial [ 33 ], a randomized trial comparing the effect of ARNI (sacubitril/valsartan) and valsartan alone in patients (with or without diabetes) with HFpEF (defined as left ventricular ejection fraction ≥ 45%) on a composite end-point of total hospitalizations for heart failure and death from cardiovascular causes.…”

Section: “Established Heart Failure Drugs” In the Treatment Of Dhfpefmentioning

confidence: 99%

Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy

Benko

Samoš

Bolek

et al. 2022

Journal of Diabetes Research

View full text Add to dashboard Cite

Diabetes is associated with several diabetic-related abnormalities which increase the risk of onset or worsening of heart failure. Recent studies showed that the majority of diabetic patients present with heart failure with preserved ejection fraction (HFpEF), and the prevalence of HFpEF in diabetics is alarming. Moreover, outcomes in HFpEF are poor and could be compared to those of heart failure with reduced ejection fraction (HFrEF), with 1-year mortality ranging between 10 and 30%. In contrast to HFrEF, there is very limited evidence for pharmacologic therapy in symptomatic patients with preserved ejection fraction, and therefore, the optimal selection of treatment for diabetic HFpEF remains challenging. This narrative review article summarizes the currently available data on the pharmacological treatment of HFpEF in patients with diabetes.

show abstract

Impact of Sacubitril–Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction

Cited by 11 publications

References 21 publications

Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials

Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials

Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure

Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy

Contact Info

Product

Resources

About